Embedded Files
Overview
Breast Cancer is a disease that impacts thousands every year. This research will examine the impact of Onametostat on the growth rate of E0771 Medullary Breast Adenocarcinoma cells in suspension cultures. 96-well plates will be seeded with cells, 30 wells will be controls, and 30 wells will be experimental across 3 trials. Cell counts will measure the growth of the cells by calculating population doubling time. A 2-sample 1-tailed t-test will determine if the differences between the two groups are statistically significant. A p-value of less than 0.05 will be considered statistically significant.
CONTEXT
E0771 Cells are derived from C57BL/6 mice and are a type of Triple-Negative Breast Cancer Cell (TNBC). TNBC can not be treated with traditional treatments because of its lack of estrogen, progesterone, and the human epidermal growth factor 2 receptors. Onametostat is a drug that inhibits an enzyme called PRMT5. PRMT5 aids in gene expression, mRNA splicing, DNA replication & repair, and cell signaling. By utilizing suspension cultures, later stages of breast cancer will be mimicked, where the cancer has metastasized and started to spread throughout the body via the bloodstream. This is significant as it becomes increasingly difficult to treat, and survival rates decrease to 12%.
Gap
While Onametostat has shown promise in other cancer types, such as glioblastoma and lung cancer, there is currently no research on the effectiveness of Onametostat in E0771 cells. This is important because all cancer types can respond differently, which can provide more insight into how other cancers will respond.
Page updated
Report abuse